Citralka dose for male with uti

Reading Document

Medical Text Search

Citralka sodium citrate dosing UTI urinary tract infection

Medical Text Search

urinary tract infection male management treatment dose

GradeResponse

No direct database results for Citralka specifically. Here is a comprehensive answer based on established pharmacology and clinical guidelines:

Citralka (Disodium Hydrogen Citrate) for UTI in Males

What is Citralka?

Citralka contains disodium hydrogen citrate as the active ingredient. It is a urinary alkalinizer — it raises urinary pH, which relieves the burning/dysuria associated with UTIs and makes the urine hostile to bacterial growth (many uropathogens prefer acidic urine).

Important: Citralka is a symptomatic/adjunct treatment. It does not replace antibiotics, especially in males where UTI is classified as a complicated UTI (due to anatomical factors).

Standard Dose

Parameter	Details
Drug	Disodium hydrogen citrate (Citralka syrup)
Standard dose	10 mL (1.4 g disodium hydrogen citrate) three times daily
Timing	After meals, diluted in a full glass of water
Duration	Typically 3–7 days for symptomatic relief

Dosing in Males with UTI

The dose is the same as in females: 10 mL TDS (three times a day) with plenty of water.
Males should always be co-prescribed an appropriate antibiotic because UTI in males is considered complicated and is more likely to involve the prostate (prostatitis) or upper tract (pyelonephritis).
Citralka alone is insufficient treatment — it only addresses dysuria and acidic urine discomfort.

How to Take

Measure 10 mL of Citralka syrup.
Dilute in a full glass of water (150–200 mL).
Take after meals, 3 times daily.
Drink plenty of fluids throughout the day (>2 L/day) to help flush bacteria.

Contraindications / Cautions

Renal impairment (sodium load and citrate accumulation risk)
Hypertension / sodium-restricted diet (each dose contains sodium)
Metabolic alkalosis
Hyperkalemia (if potassium citrate formulation is used)
Heart failure (sodium load)

Key Clinical Note for Males

UTI in any adult male is, by definition, a complicated UTI per infectious disease guidelines. Always evaluate for:

Prostatitis (most common cause of recurrent UTI in men)
Urethral stricture or BPH
Indwelling catheter
Renal calculi

Antibiotic choices typically include fluoroquinolones (ciprofloxacin, levofloxacin) or trimethoprim-sulfamethoxazole for 7–14 days, guided by urine culture and sensitivity results.

Bottom line: Citralka 10 mL TDS after food with plenty of water, as an adjunct to appropriate antibiotic therapy. The antibiotic is non-negotiable in a male with UTI.

UTI treatment can para be given in decompensated chronic liver disease patient

Medical Text Search

paracetamol safety decompensated chronic liver disease

Medical Text Search

UTI antibiotic treatment chronic liver disease cirrhosis

GradeResponse

Medical Text Search

paracetamol hepatotoxicity cirrhosis decompensated liver NAPQI glutathione

Medical Text Search

analgesic antipyretic dose reduction liver failure hepatic impairment

Paracetamol (Para) in Decompensated Chronic Liver Disease (CLD) — for UTI

Short Answer

Yes, paracetamol CAN be used, but at a reduced dose and with caution. It is actually the preferred analgesic/antipyretic in liver disease patients — NSAIDs and opioids carry greater risks.

Paracetamol Safety in Liver Disease

Condition	Recommendation
Compensated CLD	Standard dose acceptable; max 4 g/day
Decompensated CLD (cirrhosis with ascites, encephalopathy, jaundice, coagulopathy)	Reduced dose: 2–3 g/day in divided doses (per guidelines)
Active alcohol use / malnourished	Use with caution; glutathione stores depleted — lower threshold for toxicity
Acute liver failure	Avoid

Per "Prescribing Drugs of Dependence in General Practice - Opioids" (p. 81): "Paracetamol is safe in patients with chronic liver disease, but a reduced dose of 2–3 g daily is recommended for long-term use."

Why the Concern?

Paracetamol is metabolized via glucuronidation and sulfation (safe pathways), with a small fraction via CYP2E1 → NAPQI (toxic metabolite).
NAPQI is neutralized by glutathione, which is depleted in decompensated liver disease and malnutrition.
At normal doses in a decompensated liver, the NAPQI pathway becomes relatively more active → risk of hepatotoxicity increases.

Practical Dosing in Decompensated CLD with UTI

Parameter	Guidance
Dose	500 mg every 8 hours (1.5 g/day) — conservative approach
Maximum	Do not exceed 2 g/day in decompensated disease
Frequency	TDS or BD (not QDS)
Duration	Shortest effective duration
Avoid	Fasting state, concurrent alcohol, hepatotoxic drugs

What to Avoid in Decompensated CLD

Drug	Reason to Avoid
NSAIDs (ibuprofen, diclofenac)	Renal vasoconstriction → precipitates hepatorenal syndrome, worsen ascites, GI bleed risk
Opioids	Precipitate hepatic encephalopathy
Aspirin	GI bleed risk, antiplatelet effect worsens coagulopathy

Paracetamol at reduced dose remains safer than all alternatives for fever/pain in this population.

UTI Antibiotic Choice in Decompensated CLD

For the UTI itself, antibiotic selection should account for hepatic metabolism:

Nitrofurantoin — avoid (risk of hepatotoxicity, also avoid if GFR <45)
Ciprofloxacin — use with caution (partial hepatic metabolism); reduce dose if severe impairment
Trimethoprim-sulfamethoxazole — avoid in severe liver disease (sulfonamide hepatotoxicity risk)
Cephalexin / Cefuroxime — generally safe (primarily renal excretion); preferred option
Amoxicillin-clavulanate — avoid (cholestatic hepatitis risk)

Preferred antibiotic for UTI in decompensated CLD: Cephalexin 500 mg TDS × 7–14 days, guided by urine culture and sensitivity.

Bottom Line

Paracetamol: Yes, give it — but cap at 1.5–2 g/day in decompensated CLD.
Always use the lowest effective dose for the shortest duration.
Monitor LFTs if prolonged use is anticipated.
Ensure the patient is not malnourished or actively drinking alcohol.

This is a shared conversation. Sign in to Orris to start your own chat.